CRIS Curis, Inc.

Margins & Returns

Curis, Inc. is a biotechnology firm dedicated to identifying and advancing therapeutic compounds for various human cancers across the United States. Its current clinical-stage pipeline features Emavusertib, an oral small molecule presently in Phase 1/2 trials for treating non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. Another significant candidate is CI-8993, a monoclonal antibody designed to counteract the V-domain Ig suppressor of T cell activation. The company's broader development initiatives also encompass Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes, being developed for patients with MYC-altered diffuse large B-cell lymphoma. Additional candidates include CA-170, an oral small molecule aimed at advanced solid tumors and lymphomas, and CA-327, an oncology drug in its pre-investigational new drug phase. Curis has established key collaborative agreements, notably with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the co-development and marketing of Erivedge, an orally administered small molecule that inhibits the hedgehog signaling pathway for advanced basal cell carcinoma. Furthermore, it partners with Aurigene Discovery Technologies Limited on the research, development, and commercialization of small molecule compounds within the immuno-oncology and precision oncology sectors. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.